Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now
Key Stock Data
The current last sale of $19.51 is 168.73% Higher than the 52 week low.
|Intraday||Last 52 Weeks|
|High:||$ 20.17||$ 26.59|
|Low:||$ 19.31||$ 7.26|
ETFs with IOVA as a Top 10 Holding*
|Weighting||ETF Name (Symbol)||100-Day Price Change (%)|
|4.37%||Loncar Cancer Immunotherapy ETF (CNCR)||-0.82 (-3.90%)|
|3.69%||ARK Genomic Revolution ETF (ARKG)||+0.07 (0.21%)|
|*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green highlights the top performing ETF by % change in the past 100 days.|
Company Description (as filed with the SEC)
We are a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. Tumor infiltrating lymphocyte, or TIL, therapy is a platform technology that has already been studied for the treatment of metastatic melanoma and metastatic cervical cancer and other solid tumors by the National Cancer Institute, or NCI. Our lead product candidate, lifileucel for metastatic melanoma, previously known as LN-144, is an autologous adoptive cell therapy utilizing TIL, which are T cells derived from patients' tumors. We are also developing a second product candidate, an autologous adoptive cell therapy utilizing TIL for the treatment of cancers other than metastatic melanoma, which is known as LN-145. ... More ...
Nasdaq Official Price
Aug. 22, 2019
Aug. 22, 2019